Chartwatch - DXB, page-240

Cheers ovf; you're a legend.

Pretty sure there's 80k fsgs sufferers in the US though.

I've been working on the assumption that we'd treat 40k of them though.

Even at the most conservative drug pricing and a good whack of dilution, fsgs has got to be worth $7.50/ share post approval and in the market.

Definitely worth a long term hold but things should move fairly quickly; in biotech terms anyway.

This underpins the value here regardless of DKD results, etc but I'm confident that they will be good.

I've become fairly cynical over the years having endured exorbitant opportunity cost (SPL), bad decisions from management (ACL) signing an agreement with Dr Reddy's based on profit instead of revenue, and copped a flogging with (FTT) having absolutely no biological activity and no-one noticed over all of the years and 10s of millions spent...

I could add plenty more but I won't, but I like to poke holes in things I plan to hold for a while

My brother and Dad are going to buy a few too.

Again; thanks for your efforts.